-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin Completes Dosing in Part A of Pivotal Annamycin Trial for AML

PUBT·10/30/2026 12:40:30
Listen to the news
Moleculin Completes Dosing in Part A of Pivotal Annamycin Trial for AML
  • Moleculin Biotech completed Part A dosing in its pivotal Phase 2/3 MIRACLE trial for adults with relapsed or refractory acute myeloid leukemia.
  • The trial evaluates Annamycin combined with cytarabine, with comprehensive Part A results expected in the first quarter of 2027.
  • The findings will guide Annamycin dose selection for Part B across patients whose leukemia resisted or returned following prior treatment.
  • Blinded interim data continued to show no heart toxicity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300840PRIMZONEFULLFEED9856644) on October 30, 2026, and is solely responsible for the information contained therein.